425: Rafael Holdings to Merge with Cyclo Therapeutics in Deal Focused on Niemann-Pick Disease Treatment

Rafael Holdings and Cyclo Therapeutics have entered into a definitive merger agreement to focus on the development of Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1.

Summary

• Rafael Holdings and Cyclo Therapeutics have agreed to merge, focusing on developing Trappsol Cyclo for Niemann-Pick Disease Type C1.
• Cyclo Therapeutics shareholders will receive Rafael Holdings Class B common stock, with Cyclo valued at $0.95 per share.
• Rafael Holdings' valuation is based on its cash, marketable securities, and certain investments, minus current liabilities, and will account for funding Cyclo's operations through convertible notes.
• Following the merger, Rafael Holdings will fund Cyclo's TransportNPC clinical trial up to its 48-week interim analysis.
• The merger is expected to close in late 2024, pending shareholder approval, SEC effectiveness of the registration statement, and other customary conditions.
• Rafael Holdings first invested in Cyclo Therapeutics in March 2023 and has provided ongoing financial support.
• The TransportNPC Phase 3 clinical trial is fully enrolled, with 48-week interim analysis results expected in mid-2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the merger agreement, which provides financial stability for Cyclo Therapeutics and focuses on a promising drug candidate. However, there are inherent risks associated with clinical trials and regulatory approvals, preventing a higher score.

Positives

• Merger aims to accelerate the development of Trappsol Cyclo, a promising treatment for Niemann-Pick Disease Type C1.
• Rafael Holdings' financial strength will support the funding of the TransportNPC clinical trial.
• The combined entity will focus on clinical-stage assets with high unmet medical needs.
• Markus W. Sieger, a current independent member of the Companys board of directors, will be appointed to the Rafael board.

Risks

• The merger is subject to shareholder and regulatory approvals, and may not close in the anticipated timeframe or at all.
• The success of the TransportNPC clinical trial is uncertain, and interim results may not be positive.
• Integration of the two companies may present challenges.

Future Outlook

Rafael Holdings intends to focus its efforts on making Trappsol Cyclo its lead clinical program and will leverage its resources to help bring this much needed treatment option to NPC patients.

Management Comments

• Bill Conkling (President and CEO of Rafael Holdings) stated that the merger is a major step forward in their strategy to invest in and develop clinical-stage assets.
• N. Scott Fine (Chief Executive Officer of Cyclo Therapeutics) expressed pleasure with the merger agreement and believes Rafael Holdings' financial strength will benefit shareholders and patients.

Industry Context

This announcement reflects a trend in the pharmaceutical industry where larger companies acquire smaller, specialized firms to gain access to promising drug candidates and expertise in specific therapeutic areas. This merger allows Rafael Holdings to expand its pipeline and focus on rare diseases, while providing Cyclo Therapeutics with the resources needed to advance its clinical program.

Comparison to Industry Standards

• The valuation of Cyclo Therapeutics at $0.95 per share is a key factor, and its fairness would typically be assessed by financial analysts using comparable company analysis and discounted cash flow models.
• Comparable companies in the rare disease space, such as BioMarin Pharmaceutical and Sarepta Therapeutics, often trade at multiples of their revenue or potential peak sales of their key products.
• The success of Trappsol Cyclo in clinical trials will be crucial for determining the long-term value of the merged entity.
• The funding commitment from Rafael Holdings to support the TransportNPC trial is also a positive sign, as clinical development is a capital-intensive process.

Stakeholder Impact

• Shareholders of Cyclo Therapeutics will receive shares of Rafael Holdings Class B common stock.
• Patients with Niemann-Pick Disease Type C1 may benefit from the accelerated development of Trappsol Cyclo.
• Employees of Cyclo Therapeutics will become part of the Rafael Holdings organization.

Next Steps

• Obtain shareholder approval from both Rafael Holdings and Cyclo Therapeutics.
• Secure SEC effectiveness of the registration statement.
• Fulfill other customary closing conditions.
• Continue funding and executing the TransportNPC clinical trial.
• Await the 48-week interim analysis results in mid-2025.

Key Dates